搜索
Longeveron Inc
LGVN添加自选
0.670USD
-0.032-4.57%
收盘 05/15, 16:00（美东）报价延迟15分钟
15.37M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-4.57%
5天
-20.67%
1月
-39.05%
6月
-1.64%
今年开始到现在
+32.51%
1年
-52.78%
TradingKey Longeveron Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Longeveron Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名167/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.11。中期看，股价处于上升通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Longeveron Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Longeveron Inc亮点
亮点风险
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
业绩高增长
公司营业收入稳步增长，连续3年增长69.11%
业绩增长期
公司处于发展阶段，最新年度总收入1.20M美元
估值合理
公司最新PE估值-0.52，处于3年历史合理位
机构加仓
最新机构持股2.25M股，环比增加33.51%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.93
分析师目标
根据
3
位分析师
买入
评级
6.112
目标均价
+709.60%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Longeveron Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Longeveron Inc简介
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
公司代码LGVN
公司Longeveron Inc
CEOPowell (Than)
网址https://www.longeveron.com/
相关品种
